Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meloxicam - Boehringer Ingelheim

Drug Profile

Meloxicam - Boehringer Ingelheim

Alternative Names: Amelotex; Mobec; Mobic; Mobicox; Movalis; Movatec; Parocin; Tenaron; UH AC 62; UH AC 62 XX; UH AE 62 XX; Uticox

Latest Information Update: 30 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Back pain; Gout; Juvenile rheumatoid arthritis; Neuropathic pain; Osteoarthritis; Periarthritis; Rheumatoid arthritis
  • Discontinued Preterm labour

Most Recent Events

  • 06 Nov 2018 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Russia (PO) (NCT03684265)
  • 05 Oct 2018 Boehringer Ingelheim initiates enrolment in a phase I bioavailability and bioequivalence trial in healthy volunteers in Russia (PO, Capsule) (NCT03684265)
  • 25 Sep 2018 Boehringer Ingelheim plans a phase I bioavailability study in Healthy volunteers (PO) (NCT03684265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top